Education
About Us
Working with TipRanks
Follow Us
Exelixis (EXEL)
NASDAQ:EXEL
EXEL Stock Chart & Stats
$41.78
$0.17(0.50%)
At close: 4:00 PM EST
$41.78
$0.17(0.50%)
Day’s Range― - ―
52-Week Range$31.90 - $49.62
Previous CloseN/A
Volume463.09K
Average Volume (3M)3.01M
Market Cap
$11.30B
Enterprise Value$10.35B
Total Cash (Recent Filing)$988.53M
Total Debt (Recent Filing)$176.46M
Price to Earnings (P/E)17.7
Beta0.89
Next Earnings
Feb 10, 2026EPS Estimate
0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.78
Shares Outstanding268,112,150
10 Day Avg. Volume2,817,824
30 Day Avg. Volume3,007,538
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)4.39
Price to Sales (P/S)4.54
P/FCF Ratio15.55
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue4.53
Enterprise Value/Gross Profit4.68
Enterprise Value/Ebitda12.00
Forecast
1Y Price Target
$45.33Price Target Upside8.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
EPS Forecast (FY)2.9
Revenue Forecast (FY)$2.34B
Bulls Say, Bears Say
Bulls Say
Cash ReservesExelixis ended 3Q25 with roughly $1.57B in cash, cash equivalents, and marketable securities.
EarningsExelixis recorded diluted net income of $0.69 per share vs. previously forecast diluted net income of $0.56 per share.
Revenue GrowthExelixis generated $597.8M in revenue for 2Q25, with cabozantinib sales of $542.9M, vs. prior estimate of $571.5M and $526.5M, respectively.
Bears Say
Clinical RisksRisks include commercial risk with respect to Cabometyx (cabozantinib) and failure to generate favorable data from ongoing clinical programs, particularly those involving zanzalintinib.
Sales ImpactInventory for the quarter decreased roughly 9%, to 2.0 weeks on hand, which corresponds to a negative impact of roughly $8 million on Cabometyx sales.
Toxicity ConcernsExelixis’s triplet did not yield a supportive risk/benefit profile, driven by toxicity concerns from the Phase III COSMIC-313 study.
Exelixis News
EXEL FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was $31.90 and its highest was $49.62 in the past 12 months.
What is Exelixis’s market cap?
Exelixis’s market cap is $11.30B.
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Feb 10, 2026 which is in 80 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Nov 04, 2025. The company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.685 by $0.095.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Undervalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is 0.76.
How many shares outstanding does Exelixis have?
Exelixis has 268,112,150 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.78 in its last earnings report, beating expectations of $0.685. Following the earnings report the stock price went up 6.517%.
Which hedge fund is a major shareholder of Exelixis?
Currently, no hedge funds are holding shares in EXEL
Exelixis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$45.33 (8.50% Upside)
$45.33 (8.50% Upside)
Blogger Sentiment
Bullish
EXEL Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 834.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.46%
12-Months-Change
Fundamentals
Return on Equity
30.56%
Trailing 12-Months
Asset Growth
-4.62%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. is a biotechnology company focused on the development and commercialization of innovative therapies for cancer treatment. Headquartered in Alameda, California, Exelixis is primarily involved in the oncology sector, offering a range of products designed to improve the lives of patients with various types of cancer. The company’s core product is cabozantinib, marketed under the brand names Cometriq and Cabometyx, which is used for the treatment of multiple cancer indications, including renal cell carcinoma and hepatocellular carcinoma.
EXEL Company Deck
EXEL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and successful market penetration of new treatments, particularly in the oncology segment. The advancement of zanzalintinib in clinical trials and its potential new indications were key positives. However, restructuring charges and potential regulatory delays posed challenges. Overall, the positive aspects outweigh the negatives, indicating a favorable outlook.View all EXEL earnings summariesEXEL Revenue Breakdown
89.92% U.S.
7.92% Europe
2.16% Japan
EXEL Stock 12 Month Forecast
Average Price Target
$45.33
▲(8.50% Upside)
Technical Analysis
Ownership Overview
3.70% Insiders
25.62% Mutual Funds
14.23% Other Institutional Investors
28.34% Public Companies and Individual Investors